Using an AI-driven algorithm could potentially address the limitations of traditional diagnostic methods by analyzing trends in electronic health records.

Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led ...

Penpulimab in combination therapy for the first-line treatment of metastatic NPC, has had its marketing application accepted by the NMPA and the FDA. Additionally, the marketing application for its ...

Liver cancer is responsible for thousands of deaths each year - but one of the early symptoms is often ignored or mistaken ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint ... yet to share the data behind the ...

The GLP-1 receptor agonist improved both histology and fibrosis in patients, with additional improvements in their liver ...

Chemomab Therapeutics (CMMB) announced that data from its Phase 2 SPRING trial in patients with primary sclerosing cholangitis was presented at ...

Among the 62 patients with unresectable or metastatic HER2-positive (IHC 3+) disease, zanidatamab monotherapy induced ...

"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD). The ...

Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...